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complications treatment costs were the main cost driver, accounting for 67% and
77% of total direct costs of the insulin detemir therapy and NPH insulin therapy
respectively. Due to a better reduction from baseline of HbA1c the development and
progression of complications was delayed, and the cumulative incidence of diabe-
tes complications decreased for insulin detemir plus OADs therapy versus NPH
insulin plus OADs therapy. CONCLUSIONS: The results of this study demonstrate
that insulin detemir is a very cost-effective option for the treatment of type 2
diabetes compared to NPH insulin in Portugal.
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OBJECTIVES: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in
Europe and the USA. Angiotensin-converting enzyme (ACE) inhibitors slow down
the progression of renal disease and therefore provide a renal-protective effect.
The aim of our study was to assess the most cost-effective time to start an ACE
inhibitor (or an angiotensin II receptor blocker (ARB) if coughing as a side effect
occurs) in patients with newly diagnosed type 2 diabetes in the The Netherlands.
METHODS: Three strategies were compared: treating all patients at the time of
diagnosing type 2 diabetes, screening for microalbuminuria, and screening for
macroalbuminuria. A lifetime Markov decision model with simulated 50-year-old
patients with newly diagnosed diabetes mellitus was developed using published
data on costs and health outcomes and simulating the progression of renal disease.
A health insurance perspective was adopted. RESULTS: In the base-case analysis,
the treat-all strategy is associated with the lowest costs and highest benefit and
therefore dominates screening both for macroalbuminuria and microalbuminuria.
A multivariate sensitivity analysis shows that the probability of savings is 70%.
Treating all patients with an ARB would also be a dominant strategy despite the
fact that ARBs are a much more expensive alternative. CONCLUSIONS: Patients
with type 2 diabetes should receive an ACE inhibitor immediately after diagnosis if
they do not have contraindications. An ARB should be considered for those patients
developing a dry cough under ACE inhibitor therapy. The potential for cost savings
would be even larger if the prevention of cardiovascular events were considered.
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OBJECTIVES: The UK Prospective Diabetes Study (UKPDS) reported a persistence in
risk reduction of diabetes-related events associated with improved glycaemic con-
trol observed between intensive and conventional therapy groups beyond the in-
tervention period. This has important implications for projecting short-term clin-
ical trial results over long-term time horizons. The aim of this study was to
reproduce the UKPDS legacy effect and assess the impact on long-term
cost-effectiveness. METHODS: The Cardiff Type 2 Diabetes Model was initiated
with cohort profiles consistent with reported intensive versus conventional control
groups within UKPDS; initial HbA1c treatment effects were applied and modelled
over time assuming two scenarios: a loss of antihyperglycaemia benefit at year 10
or maintenance of clinical benefit (the legacy effect). Under both scenarios, risk
reductions and cost-effectiveness of sulphonylurea (SU) versus insulin were as-
sessed over a 40-year time horizon using UK 2010 costs. Both costs and health
benefits were discounted at 3.5%. RESULTS: The risk ratio (RR) of any diabetes-
related end point predicted by the model was consistent with that reported by
UKPDS when incorporating the legacy effect (RR of 0.90 versus 0.91 in the model
and UKPDS, respectively). Ignoring the legacy effect resulted in a RR of 0.99 at year
30 and a cost per quality-adjusted life-year (QALY) of £162,400, compared with
£22,565 when including the legacy effect. CONCLUSIONS: The legacy effect of in-
tensive glucose-lowering strategies has important implications when assessing
the cost-effectiveness of new therapies. Failure to include such a legacy effect, as
seen in UKPDS, may result in new therapies for managing glycaemic control ap-
pearing less cost-effective than they actually are.
PDB48
SHORT-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH
INSULIN IN INSULIN-NAÏVE SUBJECTS WITH TYPE 2 DIABETES IN SWEDEN
Ridderstråle M1, Ericsson Å2, Jensen MM3
1Department of Endocrinology, Skåne University Hospital and Department of Clinical Sciences,
University Hospital of Lund, Malmö, Sweden, 2Novo Nordisk Scandinavia AB, Malmö, Sweden,
3Novo Nordisk Scandinavia AB, Copenhagen, Denmark
OBJECTIVES: To estimate short-term cost-effectiveness of insulin detemir versus
Neutral Protamine Hagedorn (NPH) insulin based on incidence of self-treated hy-
poglycaemia and body-weight gain in insulin-naïve subjects with type 2 diabetes in
Sweden. METHODS: A short-term (one year) cost-effectiveness model was devel-
oped in Microsoft Excel® 2003. Hypoglycaemia incidence rates were based on
UKHSG data. Relative risk (RR) of hypoglycaemia, weight change and insulin doses
were obtained from randomized clinical trial data. Resource use (health care con-
tacts, blood glucose tests) and sick-leave following hypoglycaemia were estimated
from survey data. Effectiveness was expressed as quality adjusted life-years
(QALYs). Direct and indirect costs were in Swedish Kronor (SEK 1  €0.10, 2010
values) with unit costs from official sources. Probabilistic sensitivity analyses were
performed. RESULTS: Treatment with detemir was associated with fewer self-
treated hypoglycaemic events compared with NPH (RR: 0.47 [CI 0.25:0.88]) and
lower weight gain (mean difference -0.91 kg [CI -1.53;-0.28]), leading to an average
gain of 0.011 QALYs per year. Annual costs were SEK6,505 for detemir versus
SEK5,008 for NPH with an incremental cost-effectiveness ratio (ICER) of SEK139,665
per QALY gained for detemir versus NPH from a societal perspective. From a health
care perspective, annual costs were SEK5,809 for detemir and SEK3,527 for NPH
with an ICER of SEK212,909 per QALY gained for detemir versus NPH.
CONCLUSIONS: Insulin detemir can be considered cost-effective versus NPH insu-
lin in insulin-naïve subjects with type 2 diabetes in Sweden already in the first year
of treatment, both from a health care and a societal perspective, based on reduc-
tions in self-treated hypoglycemia and superior weight management. Given the
non-significant differences in HbA1c control, results of the short-term analyses is
not expected to deviate substantially if longer time horizons are applied. Higher
pharmacy costs with insulin detemir should not be a barrier to therapy based on
these findings.
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OBJECTIVES: This analysis of CHOICE presents resource use data from the six
months pre and post initiation of adult patients’ first injectable therapy for the
treatment of T2D (ExBID or INS). CHOICE is an ongoing European 6 country pro-
spective observational study. METHODS: Patient data are collected immediately
before (baseline), and 3, 6, 12, 18 and 24 months after, initiation of injectable
therapy. RESULTS: Important baseline differences between the ExBID and INS co-
horts prevent direct comparison of outcome data. In the ExBID cohort (baseline
n1177; 6 months n1073) 78.8% patients self-monitored their blood glucose
(SMBG) at baseline; 81.6% at 6 months. Mean (SD) tests/week (past 4 weeks) were
9.28 (7.93) and 8.24 (6.41) respectively. Mean (SD) number of oral antihyperglycae-
mic medications used was 1.20 (0.75) at baseline and 1.42 (0.73) at 6 months. 93.4%
patients had 1 contact with a health care professional (HCP) in 6 months before
ExBID initiation (mean [SD] 7.75 [7.49] visits); 89.1% in 6 months post initiation (7.55
[7.41]). In the INS cohort (baseline n1315; 6 months n1235), 79.8% patients SMBG
at baseline; 92.4% at 6 months. Mean (SD) tests/week were 9.91 (8.58) and 13.08
(8.46) respectively. Mean (SD) number of oral antihyperglycaemic medications used
was 0.96 (0.76) at baseline and 0.98 (0.77) at 6 months. 93.8% patients had1 contact
with a HCP in 6 months before INS initiation (mean [SD] 8.45 [9.19] visits); 93.2% in
6 months post initiation (11.11 [16.75]). Mean doses of both ExBID and INS increased
during the first 6 months post initiation. In both ExBID and INS cohorts, between-
country variability was found. CONCLUSIONS:Mean resource utilisation increased
following initiation of injectable therapy. Increases in mean test strip use/week
(32%) and mean number of contacts with HCPs (31%) were observed in the INS
cohort. Respective observations for ExBID cohort were -12.7% and -2.7%.
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OBJECTIVES: Hypercortisolism in Cushing’s Disease (CD) is associated with signif-
icant comorbidities, which improve and in some cases are reversed with biochem-
ical control (BC). The purpose of this study was to capture data describing comor-
bidity reductions with BC and estimate the potential cost savings associated with
reversal. METHODS: Comorbidity reductions with BC were identified through a
comprehensive literature search using CD AND epidemiology, morbidity, compli-
cations, BC and treatment outcomes as search terms. Selected clinical studies
detailed the relationship between comorbidity and BC in adults. In the cost analy-
sis, comorbidities were selected if reported in patients achieving BC. Literature-
based cost estimates were identified for CD-related comorbidities from the US
payer perspective, and inflated to 2010 USD. Cost ranges were reported as the
difference between expected comorbidity costs in uncontrolled and controlled pa-
tients. Sensitivity analyses were conducted to also include possibly reversible
comorbidities. RESULTS: Patients with CD experience comorbidities ranging from
back pain (86%) to psychosis (1.4%). Of 16 comorbidities identified in this study,
seven were certainly reversible in CD patients achieving BC. Hypertension and
diabetes mellitus were reversed in 44% and 40% of patients achieving BC at 1 year.
Psychiatric illness and nephrolithiasis were resolved in 76% and 50% of CD pa-
tients. In CD patients with reported impaired glucose tolerance and overweight/
obesity, 60% and 37% of cases were resolved with BC. The application of cost esti-
mates to prevalence of each reversible comorbidity before BC yielded a total per-
patient cost of $19,239-$27,600. With BC, expected comorbidity costs ranged from
$12,448-$18,312, representing a cost savings of $6,790-$9,288. Sensitivity analysis
including possibly reversible comorbidities (like back pain, osteoporosis and ver-
tebral fractures) produced estimated total cost savings of $10,571-$14,806 (incre-
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